Claims for Patent: 8,617,572

Summary for Patent: 8,617,572

Title:	Botulinum toxin treatments of depression
Abstract:	Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
Inventor(s):	Blumenfeld; Andrew M. (Del Mar, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/053,583
Patent Claims:	1. A method for treating depression comprising directly administering a botulinum toxin to a trigeminal nerve of a human patient with depression, thereby decreasing the depression. 2. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A. 3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type B. 4. The method of claim 1, wherein the method of local administration is injection. 5. A method for treating depression comprising locally administering a therapeutically effective amount of a botulinum toxin subdermally, non-intramuscularly to a trigeminal sensory nerve of a human patient with depression, thereby treating the depression by reducing the occurrence of a symptom of the depression. 6. The method of claim 5, wherein the botulinum toxin is botulinum toxin type A. 7. The method of claim 5, wherein the botulinum toxin is botulinum toxin type B.

Details for Patent 8,617,572

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2023-10-29